Masoud Kargar

Dr. Masoud Kargar


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
RGRoustaye Gourabi
Roustaye Gourabi
MJMohammad Javad
Mohammad Javad
BKBita Khanbabaei
Bita Khanbabaei
YSYalda Yarahmadi Saki
Yalda Yarahmadi Saki
ANAnita Nikoo
Anita Nikoo
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi

1 January 2025 in International Journal of Microbiology
Verified
Journal Article
Open access
ZRZohreh Riahi Rad
Zohreh Riahi Rad
HGHossein Goudarzi
Hossein Goudarzi
MGMehdi Goudarzi
Mehdi Goudarzi
PPParisa Pourdehghan
Parisa Pourdehghan
MKMasoud Kargar
Masoud Kargar
AHAli Hashemi
Ali Hashemi
Background: Since antimicrobial resistance is a rising danger and a serious threat to the health of humans, recent studies have revealed that routine tests, such as minimum inhibitory concentration (MIC), are not enough to detect heteroresistance (HR) phenotype (i.e., phenotypic heterogeneity in antibiotic susceptibility in the identical bacterial population), and medical laboratories require awareness raising to face it. Colistin is regarded as the final therapeutic option for infections caused by carbapenem‐resistant gram‐negative bacteria. In this study, we explored the presence of HR to colistin in carbapenem‐resistant Pseudomonas aeruginosa isolates in Iran. Methods: From 2019 to 2020, 100 P. aeruginosa clinical isolates were gathered from hospitals in various regions in Iran. In the present study, antibiotic susceptibility testing was used to determine antibiotic resistance. The population analysis profile (PAP) test was conducted to measure HR. Additionally, PCR was carried out to detect metallo‐ β ‐lactamase genes, including bla NDM-1 and bla IMP , and bla VIM genes of colistin heteroresistant isolates. Results: As a result, of the 100 P. aeruginosa isolates that were tested by AST, 66 were resistant to carbapenem antibiotics. Here, we found that 62 carbapenem‐resistant Pseudomonas aeruginosa (CRPA) isolates were susceptible to colistin, while four isolates were resistant to colistin. Regarding the PAP assay, we identified eight heteroresistant isolates, of which three and two isolates carried bla NDM-1 and bla IMP genes, respectively. Furthermore, the HR isolates demonstrated a stable phenotype after seven subcultures in Mueller Hinton agar (MHA) without antibiotics. Conclusions: Finally, our study highlights the interplay between HR and its diagnosis methods. Since it is difficult to detect heteroresistant isolates by routine tests in clinical laboratories, it might be misclassified as susceptible and lead to challenges for clinicians and their patients.

19 December 2025 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
NSNajmaldin Saki
Najmaldin Saki
NSNarjes Sadat Sadati
Narjes Sadat Sadati
ZZZeinab Deris Zayeri
Zeinab Deris Zayeri
MKMasoud Kargar
Masoud Kargar
Infantile hemangioma (IH) is a common benign tumor that occurs in children, affecting both blood vessels and soft tissues. Its pathological features includ

18 March 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
MKMasoud Kargar
Masoud Kargar
GKGholam Abbas Kaydani
Gholam Abbas Kaydani
BKBijan Keikhaei
Bijan Keikhaei
NSNajmaldin Saki
Najmaldin Saki
MJMohammad Ali Jalalifar
Mohammad Ali Jalalifar
Transfusion therapy is crucial for treating Transfusion-dependent thalassemia (TDT) patients. However, the production of Alloantibodies presents a substantial challenge for these individuals and impacts their quality of life. The Rh and Kell blood group antigens are particularly susceptible to alloantibody development. This study aims to establish the correlation between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 alleles and alloimmunzation in thalassemia patients from Iran. 98 thalassemic patients were recruited for this study (49 alloimmunized and 49 non-alloimmunized). Alloimmunized patients developed Rh and Kell specificities alloantibodies. The two groups were compared based on the results of HLA-DRB1 and HLA-DQB1 genotyping conducted using Sequence-Specific Primers (SSP-PCR). The findings from the antibody screening revealed that the predominant alloantibody detected was Anti-K (95.9%), Anti-E (65.3%), Anti-C (30.6%), Anti-D (28.6%), Anti-c (10.2%), Anti-e (2%), and Anti-k (2%). There was a notable difference in HLA-DQB1*03 between alloimmunized and non-alloimmunized groups, 41.8% vs. 58.2%, respectively. (iP = 0.001, OR = 0.135, CI = 0.036–0.499). There was not any notable relationship between HLA-DRB1*04 and HLA-DQB1*06 alleles and alloimmunization. Our findings indicate that HLA-DQB1*03 may have a protective role in preventing alloantibody production. Thus, HLA-typing, particularly focusing on DQB1*03, can significantly enhance the screening process, leading to improved blood transfusion management, reduced rejection of hematopoietic stem cell transplantation, and minimized blood transfusion complications.

1 January 2026 in International Journal of Microbiology
Verified
Journal Article
Open access
PDF file
MGMohammad Javad Roustaye Gourabi
Mohammad Javad Roustaye Gourabi
ANAnita Nikoo
Anita Nikoo
BKBita Khanbabaei
Bita Khanbabaei
MKMasoud Kargar
Masoud Kargar
AFAmirhossein Fayyazi
Amirhossein Fayyazi
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
β ‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β ‐lactamase enzymes. The proliferation of these enzymes represents a critical threat to global public health, compounding therapeutic challenges and escalating healthcare costs. As the efficacy of conventional treatments diminishes, reliance on last‐resort agents like carbapenems and colistin has increased, in turn accelerating resistance to these precious final‐line options. To address this escalating crisis, the strategic combination of β ‐lactam antibiotics with β ‐lactamase inhibitors (BLIs) has emerged as a vital therapeutic approach, restoring the activity of β ‐lactams by inactivating the resistance enzymes. Since the introduction of clavulanic acid, significant progress has been made in expanding the BLI arsenal. This review provides a comprehensive analysis of the current landscape of novel BLIs that have been approved or are in advanced clinical development, delving into their distinct mechanisms of action, spectra of activity against Ambler molecular classes (A, B, C, and D), and evolving clinical applications. While early inhibitors primarily targeted serine‐ β ‐lactamases (SBLs), recent advancements have introduced agents with expanded profiles, including those effective against some Class D carbapenemases. A paramount, ongoing challenge remains the development of effective inhibitors against metallo‐ β ‐lactamases (MBLs), though promising candidates like taniborbactam and xeruborbactam are now in clinical development. This review synthesizes the current knowledge on these innovative inhibitors, from recently approved combinations like ceftazidime/avibactam and cefepime/enmetazobactam to those in advanced clinical trials, and critically examines the associated therapeutic challenges, including the emergence of resistance. By integrating mechanistic insights with clinical perspectives, this article is aimed at informing the ongoing battle against antimicrobial resistance and guiding the future development of life‐saving therapeutic strategies.

1 January 2026 in BioMed Research International
Verified
Journal Article
Open access
ZRZohreh Riahi Rad
Zohreh Riahi Rad
HGHossein Goudarzi
Hossein Goudarzi
MGMehdi Goudarzi
Mehdi Goudarzi
MJMohsen Javidi
Mohsen Javidi
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
AHAli Hashemi
Ali Hashemi
Background: According to the World Health Organization 2024 bacterial priority pathogens list, carbapenem‐resistant Enterobacterales (CRE) were listed among the critical priority pathogens. Heteroresistance (i.e., a bacterial isolate that appears susceptible but harbors resistant subpopulations) represents a challenge in traditional laboratory testing, which may lead to treatment failure with colistin. This phenomenon has been studied in many bacteria, including K. pneumoniae . To our knowledge, this is the first report of colistin heteroresistance in K. pneumoniae isolates using population analysis profiles (PAPs) in Iran. Methods: Between 2019 and 2020, 100 K. pneumoniae isolates were collected from various samples of hospitalized patients in Iran. This study primarily determined antibiotic resistance by antimicrobial susceptibility testing. Thereafter, the prevalence of colistin heteroresistance in K. pneumoniae isolates was evaluated by the PAP test. Heteroresistant isolates were typed by multilocus sequence typing (MLST). Results: The MIC test showed that 79 (79%) of the 100 K. pneumoniae isolates were susceptible to colistin. Overall, 2/79 colistin‐susceptible isolates were classified as heteroresistant isolates by the PAP method, with a colistin MIC of 0.5 μ g/ml. Importantly, after 5 serial passaging on colistin‐free plates, there was no increase in the MIC of the colistin‐resistant subpopulations, showing that heteroresistance cases were unstable. MLST revealed that heteroresistant isolates belong to ST377 and ST15. Conclusions: In conclusion, the current study contributes to our understanding of the challenges posed by heteroresistant isolates in clinical laboratories. Since heteroresistant isolates may be misidentified as susceptible by standard tests, these findings raise concerns regarding the interpretation of colistin susceptibility results.